Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 213

1.

Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size.

Jain V, Hartogensis W, Bacchetti P, Hunt PW, Hatano H, Sinclair E, Epling L, Lee TH, Busch MP, McCune JM, Pilcher CD, Hecht FM, Deeks SG.

J Infect Dis. 2013 Oct 15;208(8):1202-11. doi: 10.1093/infdis/jit311.

2.

Dysfunctional phenotypes of CD4+ and CD8+ T cells are comparable in patients initiating ART during early or chronic HIV-1 infection.

Amu S, Lantto Graham R, Bekele Y, Nasi A, Bengtsson C, Rethi B, Sorial S, Meini G, Zazzi M, Hejdeman B, Chiodi F.

Medicine (Baltimore). 2016 Jun;95(23):e3738. doi: 10.1097/MD.0000000000003738.

3.

Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells.

Buzon MJ, Martin-Gayo E, Pereyra F, Ouyang Z, Sun H, Li JZ, Piovoso M, Shaw A, Dalmau J, Zangger N, Martinez-Picado J, Zurakowski R, Yu XG, Telenti A, Walker BD, Rosenberg ES, Lichterfeld M.

J Virol. 2014 Sep 1;88(17):10056-65. doi: 10.1128/JVI.01046-14.

4.

Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels.

Hey-Cunningham WJ, Murray JM, Natarajan V, Amin J, Moore CL, Emery S, Cooper DA, Zaunders J, Kelleher AD, Koelsch KK; PINT study team..

AIDS. 2015 May 15;29(8):911-9. doi: 10.1097/QAD.0000000000000625.

PMID:
25730509
5.

Early Initiation Rather Than Prolonged Duration of Antiretroviral Therapy in HIV Infection Contributes to the Normalization of CD8 T-Cell Counts.

Cao W, Mehraj V, Trottier B, Baril JG, Leblanc R, Lebouche B, Cox J, Tremblay C, Lu W, Singer J, Li T, Routy JP; Montreal Primary HIV Infection Study Group..

Clin Infect Dis. 2016 Jan 15;62(2):250-7. doi: 10.1093/cid/civ809.

6.

Factors associated with CD8+ T-cell activation in HIV-1-infected patients on long-term antiretroviral therapy.

Zheng L, Taiwo B, Gandhi RT, Hunt PW, Collier AC, Flexner C, Bosch RJ.

J Acquir Immune Defic Syndr. 2014 Oct 1;67(2):153-60. doi: 10.1097/QAI.0000000000000286.

7.

CD4 T cell nadir independently predicts the magnitude of the HIV reservoir after prolonged suppressive antiretroviral therapy.

Boulassel MR, Chomont N, Pai NP, Gilmore N, Sékaly RP, Routy JP.

J Clin Virol. 2012 Jan;53(1):29-32. doi: 10.1016/j.jcv.2011.09.018.

PMID:
22019250
8.

Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy.

Hunt PW, Cao HL, Muzoora C, Ssewanyana I, Bennett J, Emenyonu N, Kembabazi A, Neilands TB, Bangsberg DR, Deeks SG, Martin JN.

AIDS. 2011 Nov 13;25(17):2123-31. doi: 10.1097/QAD.0b013e32834c4ac1.

9.

Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy.

Le T, Wright EJ, Smith DM, He W, Catano G, Okulicz JF, Young JA, Clark RA, Richman DD, Little SJ, Ahuja SK.

N Engl J Med. 2013 Jan 17;368(3):218-30. doi: 10.1056/NEJMoa1110187.

10.

Changes in levels of T cell subpopulations to monitor the response to antiretroviral therapy among HIV-1-infected patients during two years of HIV-1 replication suppression.

Zhang JC, Zhang HJ, Li Y, Jing D, Liu Q, Zhao K, Liu QQ, Zhuang Y, Kang WZ, Sun YT.

Scand J Infect Dis. 2013 May;45(5):368-77. doi: 10.3109/00365548.2012.744465.

PMID:
23186319
11.

Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA.

Goicoechea M, Smith DM, Liu L, May S, Tenorio AR, Ignacio CC, Landay A, Haubrich R.

J Infect Dis. 2006 Jul 1;194(1):29-37.

PMID:
16741879
12.

During Stably Suppressive Antiretroviral Therapy Integrated HIV-1 DNA Load in Peripheral Blood is Associated with the Frequency of CD8 Cells Expressing HLA-DR/DP/DQ.

Ruggiero A, De Spiegelaere W, Cozzi-Lepri A, Kiselinova M, Pollakis G, Beloukas A, Vandekerckhove L, Strain M, Richman D, Phillips A, Geretti AM; ERAS Study Group..

EBioMedicine. 2015 Jul 21;2(9):1153-9. doi: 10.1016/j.ebiom.2015.07.025.

13.

Select host restriction factors are associated with HIV persistence during antiretroviral therapy.

Abdel-Mohsen M, Wang C, Strain MC, Lada SM, Deng X, Cockerham LR, Pilcher CD, Hecht FM, Liegler T, Richman DD, Deeks SG, Pillai SK.

AIDS. 2015 Feb 20;29(4):411-20. doi: 10.1097/QAD.0000000000000572.

14.

Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation.

Vinikoor MJ, Cope A, Gay CL, Ferrari G, McGee KS, Kuruc JD, Lennox JL, Margolis DM, Hicks CB, Eron JJ.

J Acquir Immune Defic Syndr. 2013 Apr 15;62(5):505-8. doi: 10.1097/QAI.0b013e318285cd33.

15.

Programmed death-1 expression on CD4⁺ and CD8⁺ T cells in treated and untreated HIV disease.

Cockerham LR, Jain V, Sinclair E, Glidden DV, Hartogenesis W, Hatano H, Hunt PW, Martin JN, Pilcher CD, Sekaly R, McCune JM, Hecht FM, Deeks SG.

AIDS. 2014 Jul 31;28(12):1749-58. doi: 10.1097/QAD.0000000000000314.

16.

Predictors of virologic response in persons who start antiretroviral therapy during recent HIV infection.

Karris MY, Kao YT, Patel D, Dawson M, Woods SP, Vaida F, Spina C, Richman D, Little S, Smith DM.

AIDS. 2014 Mar 27;28(6):841-9. doi: 10.1097/QAD.0000000000000149.

17.

Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.

Cillo AR, Hilldorfer BB, Lalama CM, McKinnon JE, Coombs RW, Tenorio AR, Fox L, Gandhi RT, Ribaudo H, Currier JS, Gulick RM, Wilkin TJ, Mellors JW.

AIDS. 2015 Oct 23;29(16):2121-9. doi: 10.1097/QAD.0000000000000810.

18.

HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.

Goujard C, Girault I, Rouzioux C, Lécuroux C, Deveau C, Chaix ML, Jacomet C, Talamali A, Delfraissy JF, Venet A, Meyer L, Sinet M; ANRS CO6 PRIMO Study Group..

Antivir Ther. 2012;17(6):1001-9. doi: 10.3851/IMP2273.

PMID:
22865544
19.

HIV DNA subspecies persist in both activated and resting memory CD4+ T cells during antiretroviral therapy.

Murray JM, Zaunders JJ, McBride KL, Xu Y, Bailey M, Suzuki K, Cooper DA, Emery S, Kelleher AD, Koelsch KK; PINT Study Team..

J Virol. 2014 Mar;88(6):3516-26. doi: 10.1128/JVI.03331-13.

20.

Cellular HIV-1 DNA levels in patients receiving antiretroviral therapy strongly correlate with therapy initiation timing but not with therapy duration.

Watanabe D, Ibe S, Uehira T, Minami R, Sasakawa A, Yajima K, Yonemoto H, Bando H, Ogawa Y, Taniguchi T, Kasai D, Nishida Y, Yamamoto M, Kaneda T, Shirasaka T.

BMC Infect Dis. 2011 May 24;11:146. doi: 10.1186/1471-2334-11-146.

Supplemental Content

Support Center